Saki Matsumoto

Engineering T cell-engaging bispecific antibodies targeting KRAS G12V neoantigen across HLA-A*11:01 and HLA-A*03:01

Abstract Background T cells recognize tumor-specific neoantigens presented by human leukocyte antigen (HLA) molecules and can mediate potent antitumor immunity. However, most neoantigens are patient-specific, limiting their broad therapeutic applicability. KRAS G12V is a recurrent oncogenic mutation found in multiple c...